



Claims

1. The compound 3,3,3-trifluoro-*N*-((1,4-*trans*)-4-((3-((*S*)-2-methylmorpholino)-1*H*-pyrazolo[3,4-*d*]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide, having the Formula (I):




or a salt thereof.

2. The compound of Formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.
3. The compound of Formula (I) according to claim 1, having the Formula (I):



4. A pharmaceutical composition comprising a compound according to any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier.
5. A combination comprising (a) a compound of Formula (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, and (b) at least one additional therapeutic agent.
6. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, for use in therapy.
7. Use of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of leishmaniasis.
8. Use of a compound according to claim 7, wherein the leishmaniasis is visceral leishmaniasis.
9. The compound which is 3,3,3-trifluoro-*N*-((1,4-*trans*)-4-((3-((*R*)-2-methylmorpholino)-1*H*-pyrazolo[3,4-*d*]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide:



or a salt thereof.

10. A mixture comprising (a) a compound of Formula (I) according to claim 1, or a salt thereof, and (b) the opposite enantiomer of a compound of Formula (I) which is 3,3,3-trifluoro-*N*-((1,4-*trans*)-4-((3-((*R*)-2-methylmorpholino)-1*H*-pyrazolo[3,4-*d*]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamide, or a salt thereof.